Semaglutide Side Effects: What Research Reports

TL;DR

Semaglutide side effects in the STEP 1 trial were mostly gastrointestinal: nausea, diarrhea, vomiting, and constipation (Wilding et al., NEJM 2021; doi:10.1056/NEJMoa2032183). Any gastrointestinal event was reported in about 74 percent of the semaglutide group versus about 47 percent on placebo, and nausea was the single most common event at about 44 percent. About 7 percent of the semaglutide group stopped the drug because of adverse events, versus about 3 percent on placebo. The trial described most gastrointestinal events as mild to moderate, appearing mainly during dose escalation. These are group rates from one trial, not a prediction for any individual.

What are the most common semaglutide side effects?

The most common semaglutide side effects reported in the STEP 1 trial were gastrointestinal: nausea, diarrhea, vomiting, and constipation (Wilding et al., NEJM 2021).

STEP 1 was a 68-week phase 3 trial that randomized 1,961 adults with overweight or obesity to once-weekly semaglutide 2.4 mg or placebo (Wilding et al., NEJM 2021; doi:10.1056/NEJMoa2032183). The semaglutide group lost about 14.9 percent of body weight on average, versus about 2.4 percent for placebo. Alongside that finding, the authors tracked adverse events in both groups, and complaints from the digestive system stood out as the main safety signal. The authors reported that nausea and diarrhea were the most common adverse events and that they were typically transient and mild to moderate in severity.

How often did nausea and other GI effects occur in the trial?

In STEP 1, gastrointestinal events affected about 74 percent of the semaglutide group, led by nausea at about 44 percent (Wilding et al., NEJM 2021).

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

All values are approximate and rounded, as reported in Wilding et al., NEJM 2021. Percentages describe trial participants, not any single person's likelihood. The authors reported that these events were most often mild to moderate in severity, and they were the leading reason some participants left the study early.

How many people stopped semaglutide because of side effects?

In STEP 1, about 7 percent of the semaglutide group stopped the drug because of adverse events, compared with about 3 percent on placebo (Wilding et al., NEJM 2021).

Gastrointestinal events were the main reason for stopping. The authors reported that adverse events led to stopping the trial regimen in about 7.0 percent of the semaglutide group and about 3.1 percent of the placebo group, and that gastrointestinal events specifically accounted for about 4.5 percent versus about 0.8 percent (Wilding et al., NEJM 2021). That gap means most participants continued semaglutide through the 68-week trial despite the higher rate of digestive complaints.

Did the semaglutide trial report any serious side effects?

Serious adverse events were reported in about 9.8 percent of the semaglutide group versus about 6.4 percent on placebo, with gallbladder-related events among the differences (Wilding et al., NEJM 2021).

Serious adverse events, a category that includes any event judged medically important, occurred in about 9.8 percent of the semaglutide group and about 6.4 percent of the placebo group (Wilding et al., NEJM 2021). Gallbladder-related disorders, such as gallstones (cholelithiasis), were reported more often on semaglutide, at about 2.6 percent versus about 1.2 percent on placebo. These figures come from one trial population and do not describe risk for any individual.

When did semaglutide side effects appear during the trial?

The trial reported that gastrointestinal events clustered around the dose escalation period and were mostly transient (Wilding et al., NEJM 2021).

In STEP 1, participants received once-weekly semaglutide titrated over 16 weeks to a maintenance dose of 2.4 mg (Wilding et al., NEJM 2021). The authors described GI events as typically appearing during dose increases and then easing, with most rated mild to moderate. This page reports the schedule used in the trial. It does not tell you what dose to take or how to titrate; those decisions belong to a qualified clinician. For the dosing schedule the trial used, see the semaglutide dosage page linked below.

How do semaglutide side effects compare with tirzepatide?

Both are GLP-1 based therapies with gastrointestinal-predominant side-effect profiles, and a head-to-head trial reported GI events as the most common adverse events for each (Frias et al., NEJM 2021; doi:10.1056/NEJMoa2107519).

SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes and found that the most common adverse events for both drugs were gastrointestinal, mainly nausea, diarrhea, and vomiting (Frias et al., NEJM 2021). Note that this trial used a 1 mg semaglutide dose, which is lower than the 2.4 mg used in STEP 1, so numbers are not directly comparable across trials. In the separate SURMOUNT-1 trial, tirzepatide produced up to about 22.5 percent mean weight loss and also reported GI events as the most common adverse effects (Jastreboff et al., NEJM 2022; doi:10.1056/NEJMoa2206038). For a fuller side-by-side, see the comparison page linked below.

Is semaglutide safe for you?

This page cannot answer that; it reports what clinical trials measured, and any personal decision belongs with a qualified clinician.

The figures above come from controlled trials with specific participants, doses, and monitoring. They describe group rates, not your individual risk. Peptara Labs provides research compounds and educational summaries; it does not provide medical advice or clinical care. If you are weighing semaglutide for any personal use, discuss your history, medications, and monitoring with a licensed clinician.